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Pharmaceutics
deliver benzocaine-a local anesthetic to treat sore throats. 
This delivery system is simply placed on a patient’s tongue 
or any oral mucosal tissue. Instantly wet by saliva, the film 
rapidly hydrates and adheres onto the site of application. 
It then rapidly disintegrates and dissolves to release the 
medicament for mucosal absorption or, with modifications, 
allows oral gastrointestinal absorption with a quick-
dissolving aspect.[1]
Advantages of rapidly dissolving films
•  Ease of administration to patients who cannot swallow, 
such as the elderly, stroke victims and bedridden 
patients; patients who should not swallow, such as 
renal failure patients; and who refuse to swallow, such 
as pediatrics, geriatric, and psychiatric patients.
•  Patient’s compliance for disabled bedridden patients 
and for traveling and busy people who do not have 
INTRODUCTION
Rapidly dissolving films (RDFs) have recently gained 
popularity in the form of breath fresheners. These films 
are placed in the mouth and dissolve quickly to release 
the flavor. Rapidly dissolvable films were developed on 
the technology of transdermal patch. RDFs are already 
being used in breath-freshening products from Warner 
Lambert and Wrigley’s in the US and Europe. Zengen 
recently launched a chloraseptic relief strip in the US to 
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ready access to water.
•  More rapid drug absorption from the pregastric area, 
i.e., mouth, pharynx, and oesophagus which may 
produce rapid onset of action.
•  Pregastric absorption can result in improved 
bioavailability, reduced dose, and improved clinical 
performance by reducing side effects.
Epilepsy is a chronic condition characterized by the 
repeated attacks of epileptic seizures. Epileptic seizures 
can occur in nonepileptic patients subjected to a variety 
of stresses and stimuli. Epileptic seizures differ from other 
types of paroxysmal attacks by their clinical expression and 
by their mechanism. The epileptic seizures and paroxysmal 
attacks are expressed on the electroencephalogram by the 
epileptic discharge.[2]
Phenobarbital, the longest-acting barbiturate, is used for 
its anticonvulsant and sedative-hypnotic properties in 
the management of all seizure disorders except absence. 
Absorbed in varying degrees following oral, rectal or 
parenteral administration. The salts are more rapidly 
absorbed than are the acids. The rate of absorption is 
increased if the sodium salt is ingested as a dilute solution 
or taken on an empty stomach. Phenobarbitone is the 
clinically effective anticonvulsant enhances the inhibitory 
effect of gamma aminobutyric acid (GABA) by facilitating 
the GABA-medicated opening of chloride channels.[3]
An attempt was made in the present investigation to prepare 
fast dissolving drug delivery systems of phenobarbital by 
solvent-casting method for rapid therapy of epileptic 
seizures.
MATERIALS AND METHODS
Materials
Phenobarbital was a gift sample obtained from Anglo-
French Drugs and Industries Ltd, Bangalore, India. 
Methocel – E 15, E 50 obtained from Dow Chemical 
Company, Mirland. Pectin and Pullulan were obtained 
from Lipoid GmbH, Germany. Hydroxypropyl cellulose, 
Gelatin, Xanthan Gum, Propylene Glycol and Aspartame 
were obtained from S.D. Fine-Chem Ltd., Mumbai, India. 
Sodium Starch Glycolate and Croscarmellose Sodium were 
obtained from DMV— Fonterra Excipients, Netherlands. 
INDION-414 was obtained from Ion Exchange India 
Ltd., Ankaleshwar, India. Other chemicals used were of 
analytical grade and procured from S.D. Fine Chemicals 
(Mumbai, India). Concentrations of Phenobarbital 
were measured with a UV–VIS spectrometer (UV-1700, 
Shimadzu Corporation, Tokyo, Japan). Interaction between 
Phenobarbital and polymers was verified using FTIR and 
TLC techniques.
Optimization of the components for formulation of 
placebo fast dissolving films
The placebo films were prepared by solvent-casting 
method. Hydroxypropylmethyl cellulose (HPMC) is known 
for its good film forming properties and has excellent 
acceptability. Hence, HPMC namely Methocel E15 was 
evaluated to optimize the effective concentration keeping 
the other components of the formulations to a constant 
mean value. Similarly an identical approach was used 
to optimize the other components such as secondary 
film modifier (pectin), film modifier (Xanthan gum) and 
plasticizer (propylene glycol) using the previously optimized 
concentration of respective components. The general 
method for preparation of placebo film is as follows. 
Previously primary film former, secondary film formers 
and film modifiers were soaked in water for 4 h and then 
uniformly dispersed to obtain dispersion. Aspartame 
and plasticizers were uniformly dissolved in 5 ml of 
95% (v/v) ethanol. Alcoholic solution and the polymeric 
dispersion were mixed to obtain a homogenous dispersion. 
Ten milliliters of the dispersion was cast onto each petri 
dish which was lubricated with olive oil. The dispersion 
was dried in a hot air oven at 40–45°C. The films were 
carefully removed from petri dishes and cut into strips 
of dimensions 3 × 3 cm and stored in an air tight glass 
bottle. The films were evaluated for imperfections and 
cuts, mechanical strength, thickness, and dissolution time.[4]
Preparation of the phenobarbital containing fast 
dissolving films
Phenobarbital (PBT) containing fast dissolving films were 
fabricated as per the method described for the fabrication 
of blank fast dissolving films. PBT was incorporated in 
5 ml of 95% (w/v) ethanolic solution and the rest of 
the procedure was same as that for the fabrication of 
blank fast dissolving films. Superdisintegrants (sodium 
starch glycolate or croscarmellose sodium) was uniformly 
dispersed in aqueous dispersion. The compositions of PBT 
containing films are shown in Table 1.
Evaluation of formulated mouth dissolving films
Film thickness
Thickness of films was measured using calibrated dial caliper.[4]
Weight variation
The study was carried out on ten films obtained from Journal of Young Pharmacists Vol 3 / No 3  183
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each formulation batch. The mean weight of film as 
well as the deviation from the mean was calculated and 
recorded.[5]
Hydration study (water uptake/swelling study)
The film sample was weighed and placed on a preweighed 
stainless steel wire mesh. The wire mesh was then 
submerged in a petridish containing 20 ml distilled water. 
Increase in weight of the film was determined at regular 
time intervals until a constant weight was obtained.[6,7]
The hydration ratio of the film was calculated using 
following formula:
t o 
o
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% Hydration ratio 100, 
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where Wt = weight of film at time t and Wo= weight of 
film at zero time.
Moisture loss (moisture vapor transmission)
The percent moisture loss was determined by placing 
prepared film in desiccators containing anhydrous calcium 
chloride. After three days, the film was taken and reweighed. 
The percent moisture loss was calculated using following 
formula:[8,9]
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where Wo = initial weight and Wt = final weight.
Percent elongation at break
The prepared film was pulled by means of a pulley   
system.[10] Weights were gradually added to the pan to 
increase the pulling force till the film was broken. The 
elongation was determined by noting the distance traveled 
by pointer before break of film on the graph paper. The 
percent elongation at break was calculated by using formula:
( )
2
1
o
Percent elongation at break mm
L 100
,
L cross sectional area
-
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where L1 = increase in the length, Lo= initial length.
Tensile strength
Film strip of dimension 5 × 2 cm2 and free from air 
bubbles or physical imperfections was held between two 
clamps positioned at a distance of 3 cm apart. A cardboard 
was attached on the surface of the clamp via a double sided 
tape to prevent the film from being cut by the grooves of 
the clamp. During measurement, the strips were pulled at 
the bottom clamp by adding weights in pan till the film 
breaks. The force was measured when the films broke. 
Results from film samples, which broke at and not between 
the clamps were not included in calculations:[11]
Tensile strengthk gm m
Breaking force F
Cross-sectional 
2 / ()
= ()
a area of sample A ()
Folding endurance
This parameter was determined by repeatedly folding one 
film at the same place till it broke. The number of times the 
film could be folded at the same place without breaking/
cracking give the value of folding endurance.[8,9]
Drug content and content uniformity
The drug content and content uniformity test was 
performed to ensure uniform and distribution of drug. 
3 cm2 films was cut, weighed and dissolved in 100 ml 
methanol. Three milliliters of supernatant aqueous solution 
was withdrawn and transferred in 100 ml volumetric flask. 
Final dilution up to mark was done using simulated saliva 
and analyzed spectroscopically at 254 nm wavelength. The 
concentration of phenobarbital (in µg/ml) was calculated 
by using standard calibration curve of phenobarbital. 
Content uniformity of phenobarbital films were done by 
selecting randomly five 3 cm2 films from different batches 
and performing study same as drug content.[4]
In vitro disintegration and dissolution time
The disintegration time is the time when a film starts to break 
or disintegrate. The dissolution time is the time when the film 
completely dissolves. The in vitro disintegration and dissolution 
time of fast-dissolving films was determined visually in a 
glass dish of 25 ml distilled water with swirling every 10 s. 
Disintegration and dissolution time was measured.[4]
In vitro dissolution study (drug release rate study)
The in vitro dissolution test was carried out in USP basket type 
Table 1: Compositions of phenobarbital  
mouth-dissolving films
Ingredients F1 F2 F3 F4 F5 F6 F7
Phenobarbital 117 117 117 117 117 117 117
METHOCEL- E 15 150 150 150 150 150 150 150
Pectin 50 50 50 50 50 50 50
HPC (low viscosity grade) 25 25 25 25 25 25 25
Menthol 40 40 40 40 40 40 40
Aspartame 3 3 3 3 3 3 3
Glycerol 125 125 125 125 125 125 125
Xanthan gum 10 10 10 10 10 10 10
Sodium starch glycolate - 50 100 150 - - -
Croscarmellose sodium - - - - 50 100 150
Propylene glycol 100 100 100 100 100 100 100
Water 5 5 5 5 5 5 5
Ethanol 7 7 7 7 7 7 7
All the weights are taken in mg, except water and ethanol taken in ml184   Journal of Young Pharmacists Vol 3 / No 3
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apparatus.[12,13] Samples of PBT-loaded films were equivalently 
containing 15 mg (3 cm2) was cut and placed basket. The 
dissolution medium consisted of 500 ml freshly deionized 
simulated saliva (pH 6.8), maintained at 37 ± 1°C and stirred at 
100 r/min. Samples of 1 ml were withdrawn at predetermined 
time intervals and replaced with fresh medium. The samples 
were filtered through Whatman filter paper and PBT 
concentrations were assayed spectrophotometrically at 254 
nm after final appropriate dilution.
The dissolution profile of conventional marketed tablet 
LUMINAL® containing 15 g equivalent phenobarbital was 
also determined using same experimental setup.
Surface morphology study using scanning electron microscopy
The surface morphology of formulated PBT film was 
assessed using a scanning electron microscope. Samples 
were mounted on round brass stubs (12 mm diameter) 
using double-backed adhesive tape and then sputter coated 
for 8 min under argon atmosphere with gold before 
examination under the scanning electron microscope. 
Pictures were then taken at an excitation voltage of 15 kV.[9]
Stability studies
Stability tests are the series of tests designed to obtain 
information on the stability of the pharmaceutical product 
in order to define its shelf life and utilization period under 
specified packaging and storage conditions.
From the seven batches of PBT films, optimized 
formulation was tested for stability studies. Films 
of optimized formula were stored at two different 
storage conditions namely 30°C ± 0.5/60 ± 1% RH and 
40°C ± 0.5/75 ± 1% RH. Each film was wrapped in a 
butter paper followed by aluminium foil and placed in an 
aluminium pouch, which was heat-sealed at the end. The 
films were evaluated for weight, PBT content and in vitro 
drug release after storage for 10, 20, and 30 days. The values 
for in vitro PBT release from the films were calculated and 
were compared for change in the dissolution profile.[4]
In-vivo animal safety study (irritation study)
The in vivo animal safety study is carried out to find safety 
of films in oral cavity. Hamster cheek pouch was selected 
as model for study.[14]
Either sex of Hamster of 100–150 g was selected for 
study. They were housed individually in an environmentally 
controlled room with 12 h light/dark cycle and had free 
access to food and water. After 7 days acclimatization 
period, they were randomly selected for different 
experimental groups.
All the experimental procedures were carried out in 
accordance with committee for the purpose of control and 
supervision of experiments on animal (CPCSEA) guidelines. 
The study was reviewed and approved by the Institutional 
Animal Ethics Committee (JNMC/IAEC/2/28/2008). J.N. 
Medical College, KLE University, Belgaum, India.
Experimental study design in hamsters
Group: I Normal or placebo film treated group.
Group: II PBT film treated group.
The placebo or PBT film was placed twice a day for 4–5 
consecutive days. The prepared PBT film sample was 
placed in cheek pouch of hamster for 10 min and then 
rinsed using distilled water. Then pouch was observed for 
any adverse effects (irritation), redness immediately and 
after 24 h interval.
RESULTS AND DISCUSSION
Thickness
The thicknesses of formulated films were found to be 
in range of 13.76 ± 0.539 to 14.3334 ± 0.0506 mm. The 
mean values are tabulated in Table 2. The values are almost 
uniform in all formulations. Obtained results has shown that 
increase in film thickness decreases tensile strength while 
increases % elongation. Further increases in thickness of film 
increases crystallinity of film and decrease dissolution rate.
Weight variation test
The percentage weight variation for all the formulation 
is tabulated in Table 2. All the films passed weight 
variation test as the % weight variation was within the 
pharmacopoeial limits of ±7.5%. It was found to be in 
range of 110.2 ± 0.20 to 127.2 ± 0.30 mg. The weight of 
all the films was found to be uniform.
Hydration study (water uptake/swelling study)
The hydration ratio defines the ability of films to absorb 
water from environment or from dissolution media. It is 
also termed as water uptake study. Hydration ratio gives 
an idea of films dissolution time and disintegration time. 
Higher values of hydration ratio indicate that films dissolve 
faster and easily. Hydration ratio values of all formulation 
are shown in Table 2. Increase in concentration of 
superdisintegrant increases hydration ratio or water uptake 
and decrease disintegration and dissolution time. F3 and 
F6 formulations showed higher hydration ratio while F1 
formulation shows low hydration ratio.Journal of Young Pharmacists Vol 3 / No 3  185
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Moisture loss (moisture vapor transmission)
MVT is defined as the quantity of moisture transmitted 
through unit area of film in unit time. The moisture loss 
study gives an idea about films stability nature and ability 
of films to withstand its physicochemical properties under 
normal conditions. It also gives idea about hydrophilicity 
of film formulations. The obtained results are tabulated 
in Table 2. The obtained values are almost uniform and 
ranges from 1.024 ± 0.004% to 2.995 ± 0.002%. F1, F5, 
and F6 formulation showed high % moisture loss while F2 
and F3 formulations showed low % moisture loss.
Tensile strength
The tensile testing gives an indication of the strength and 
elasticity of the film, reflected by the parameters, tensile 
strength (TS), elastic modulus (EM) and elongation at 
break (E/B). A soft and weak polymer is characterized 
by a low TS, EM, and E/B; a hard and brittle polymer is 
defined by a moderate TS, high EM and low E/B; a soft 
and tough polymer is characterized by a moderate TS, low 
EM and high E/B; whereas a hard and tough polymer is 
characterized by a high TS, EM and E/B. Tensile strength 
of all prepared formulation is shown in Table 3. Results 
revealed that formulations showed better tensile strength 
and less to moderate % elongation.
Tensile strength was found in range of 0.462 ± 0.007 to 
0.808 ± 0.004 kg/mm2. There is no significant change 
in the tensile strength of all formulations. Addition 
of superdisintegrants (SD) affects tensile strength 
and also % elongation. An optimum concentration of 
superdisintegrant showed improvement of tensile strength, 
but at higher concentration there was no further increase in 
tensile strength. Higher concentration of superdisintegrant 
increases thickness and crystallinity of films which causes 
decrease in tensile strength as well as percent elongation.
Percent elongation
Percent elongation is mainly based on tensile strength 
of films. The nature of polymers affects tensile strength 
and % elongation. Soft and brittle polymer increases 
tensile strength and decreases % elongation while hard 
and tough polymer increases tensile strength as well 
as % elongation. % Elongation of all formulation is 
tabulated in Table 3. The values of % elongation are in 
range of 4.108 ± 0.001% to 6.143 ± 0.001%. Increase in 
concentration of superdisintegrant decreases % elongation 
which indicates that elasticity and softness of film decreases 
which helps in fast dissolution of films.
Folding endurance
Folding endurance measures the ability of patch to withstand 
rupture, higher the folding endurance lower will be chances of 
film to rupture easily and vice versa. The folding endurance 
of all formulations is tabulated in Table 3. Increase in 
concentration of superdisintegrants increases folding 
endurance of films but after specific concentration increase 
in concentration of superdisintegrants decreases folding 
endurance. This was due to increase in crystallinity of film 
and also film thickness. More the thickness of lower will 
be folding endurance. F3 and F6 formulation showed high 
folding endurance 55.67 ±1.15 and 46.33 ± 0.57, respectively.
Drug content and content uniformity study
The drug content and content uniformity test was performed to 
ensure uniform and accurate distribution of drug. The content 
uniformity was performed for all the seven formulations 
and results are tabulated in Table 2. Five trials from each 
formulation were analyzed spectrophotometrically. The mean 
value and standard deviation of all the formulations were 
calculated. The results indicated that in all the formulations the 
drug content was uniform. The cumulative percentage drug 
released by each film to the in vitro release studies was based on 
the mean content of the drug present in the respective film.
In vitro disintegration time dissolution time test
The disintegration time is the time when a film starts to 
break or disintegrate. The dissolution time is the time when 
Table 2: Thickness, mean weight (mg), drug content (mg), %hydration ratio, %moisture loss of mouth dissolving 
films of phenobarbital
Formulation Thickness Mean weight (mg)a Drug content (mg)b % Hydration ratioa % Moisture lossa
F1 13.9166 ± 0.045 110.2 ± 0.20 13.65 ± 0.05 0.808 ± 0.004 2.995 ± 0.002
F2 14.3054 ± 0.0986 117.3 ± 0.25 16.29 ± 0.076 0.727 ± 0.003 1.024 ± 0.004
F3 14.22 ± 0.0239 121.8 ± 0.95 18.71 ± 0.26 0.616 ± 0.002 1.426 ± 0.005
F4 13.76 ± 0.539 119.3 ± 0.30 17.13 ± 0.13 0.518 ± 0.005 1.973 ± 0.003
F5 13.9722 ± 0.050 127.2 ± 0.30 14.50 ± 0.076 0.701 ± 0.001 2.203 ± 0.003
F6 14.3334 ± 0.050 123.6 ± 0.20 19.75 ± 0.17 0.505 ± 0.001 2.346 ± 0.001
F7 14.1388 ± 0.0326 119.1 ± 0.20 13.92 ± 0.047 0.462 ± 0.007 2.016 ± 0.002
aSignificance value P > 0.0001, bSignificance value P > 0.001, n = average of triplicate was determined186   Journal of Young Pharmacists Vol 3 / No 3
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the film completely dissolves. Disintegration time and 
dissolution time of formulated films is tabulated in Table 3. 
Results revealed that addition of superdisintegrants 
decreases the disintegration time and dissolution time. 
Disintegration time and dissolution time of all formulation 
were in range of 23.33 ± 1.00 to 31.33 ± 0.577 s and 
72.33 ± 1.528 to 126 ± 0.58 s, respectively.
In vitro dissolution study (drug release rate study)
Cumulative drug release and cumulative % drug 
retained were calculated on the basis of drug content of 
phenobarbital present in the respective film. The results 
obtained in the in vitro drug release for the formulations F1 
to F7 and marketed tablet “LUMINAL®” is tabulated in 
Table 4. The plots are depicted in Figure 1 (a and b) for % 
cumulative drug release versus time. Formulation F1, F2, 
F3, shows drug release up to 87.836%, 89.282%, 96.574%, 
respectively, at end of 14 min. Rapid drug dissolution was 
observed in F4, F5, F6, and F7 which release 96.307%, 
88.442%, 93.735%, and 95.114%, respectively, at end of 
14 min. F3 formulation shows highest percent of drug 
release (96.574%) than other formulations. The observed 
rapid dissolution might be due to fast disintegration 
of films and rapid dissolution of drug. Increase in 
the concentration of superdisintegrants increases 
dissolution rate of drug which was observed in F3, F4, 
F6 formulation, but further increase in concentration 
of superdisintegrants will not increases dissolution rate 
much more which was observed in film F4, F7. Also 
increase in the concentration of superdisintegrants causes 
precipitation of films and decreases tensile strength and 
folding endurance. This is observed at concentration 
of ≥2% of the film. The drug release was completely 
achieved in a shorter duration of time. In vitro release 
rate study of F3 formulation vs. conventional marketed 
tablet LUMINAL® containing 15 mg phenobarbital has 
shown that F3 release found to be faster and complete 
within 15 min. In vitro release of LUMINAL® was found 
to be 15% in 14 min and up to 46% at half an hour. 
The correlation coefficient values obtained are shown 
in Table 5. The results were found to be linear for first-
order release. It is concluded that release of drug from 
formulations F1–F7 followed first order.
Surface morphology study using scanning electron 
microscopy
SEM was performed on the films to assess changes in their 
surface morphology prior to and after dissolution testing 
and is depicted in Figure 2 (a–c). A smooth and compact 
surface with crystals of phenobarbital was noted at time 
0 min for the optimized film F3. As dissolution time 
progressed to the first minute, film appeared porous. After 
1 min the surface morphology of films showed significant 
changes in texture, to the extent that the film developed 
clearly visible pores with solubilization of phenobarbital 
crystals. SM of pure drug was also taken and it showed 
crystalline nature of phenobarbital.
Stability studies
F3 formulation was selected for stability studies on the basis 
of high cumulative % drug release and also results of in vitro 
disintegration time. From these results it was concluded 
Table 4: In vitro release profile of phenobarbital mouth 
dissolving film formulations
Time 
(min)
Cumulative % drug released
F1 F2 F3 F4 F5 F6 F7 LUMINAL®
1 16.781 18.935 23.117 22.672 17.648 20.592 21.668 0.264
2 28.420 29.225 37.169 35.966 27.640 27.744 33.679 0.794
3 40.257 39.181 47.094 46.891 37.553 33.631 45.624 1.591
4 47.997 45.665 55.892 55.974 45.648 41.376 54.993 2.393
5 56.048 54.404 66.182 65.513 53.921 49.814 64.147 3.463
6 66.290 67.891 76.921 70.759 64.645 60.643 73.747 4.407
7 72.022 74.791 84.697 84.721 72.886 67.230 78.642 5.488
8 77.785 78.333 90.806 89.120 79.434 77.632 88.187 6.707
9 80.355 83.329 92.349 91.233 83.475 83.006 91.175 7.932
10 82.937 84.563 93.636 92.404 84.595 87.496 92.196 9.165
11 84.054 86.062 94.401 93.307 85.719 90.444 93.088 10.932
12 85.578 87.045 95.168 94.621 86.847 91.451 93.850 12.312
13 86.839 88.162 95.805 95.39 87.577 92.461 94.614 13.700
14 87.836 89.282 96.574 96.307 88.442 93.735 95.114 14.831
Table 3: Tensile strength, %elongation, folding endurance, disintegration time, dissolution time of mouth-dissolving 
films of phenobarbital
Formulation Tensile strengtha kg/mm2 % Elongationa at break Folding endurancea Disintegration timea (s) dissolution timea (s)
F1 0.808 ± 0.004 6.143 ± 0.001 45 ± 1 31.33 ± 0.577 126 ± 0.58
F2 0.727 ± 0.003 5.144 ± 0.001 50 ± 2 27 ± 1.00 94.00 ± 1.0
F3 0.616 ± 0.002 5.132 ± 0.001 55.67 ± 1.1 23.33 ± 1.155 73.67 ± 1.528
F4 0.518 ± 0.005 4.114 ± 0.001 44.00 ± 2 23.33 ± 1.00 72.33 ± 1.528
F5 0.701 ± 0.001 5.141 ± 0.001 40.67 ± 0.57 28 ± 1.00 99.33 ± 1.528
F6 0.505 ± 0.001 4.118 ± 0.001 46.33 ± 0.57 26 ± 0.577 79.33 ± 1.528
F7 0.462 ± 0.007 4.108 ± 0.001 37.67 ± 0.57 24.33 ± 1.155 76.00 ± 2.0
a: significance value P > 0.0001, n = Average of triplicate was determinedJournal of Young Pharmacists Vol 3 / No 3  187
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CONCLUSIONS
Mouth dissolving films of Phenobarbital could be formulated 
with available low viscosity film formers viz. HPMC E15, 
Pectin, HPC, Xanthan gum. Phenobarbital, a poorly water 
soluble drug could be successfully incorporated in mouth 
dissolving film with the help of propylene glycol as solubilizer 
and plasticizer. In the present study successful optimization 
was done to study the influence of film formers, film modifier, 
plasticizers and superdisintegrants (SDs) in mouth dissolving 
films. Use of plasticizers in combination could give better 
results to films in respect to physicochemical parameter, 
such as tensile strength, %elongation, folding endurance and 
flexibility. Incorporation of superdisintegrants in the mouth 
dissolving film could be useful for rapid disintegration and 
dissolution time. Amongst all the developed formulations, 
phenobarbital mouth-dissolving film formulated using 
sodium starch glycolate (SSC) as superdisintegrant in 
concentration range of 1% (w/v), showed good in vitro 
disintegration and dissolution time.
In comparison with available marketed formulation, it has 
found that formulated films showed improved dissolution.
The in vitro drug release, in vitro stability evaluation and 
physicochemical/mechanical results obtained in this work, 
confirm the potentials of the mouth dissolving film of 
phenobarbital as a promising candidate for quick relief 
from epileptic seizures and attacks with better patient 
Table 5: Model fitting of the release profile using five 
different models (R value)
Formulation 
code
Mathematical models (Kinetics)
Zero order First order Higuchi Best fit kinetic
F1 0.882 0.978 0.912 First order
F2 0.885 0.961 0.927 First order
F3 0.844 0.974 0.891 First order
F4 0.855 0.979 0.901 First order
F5 0.890 0.955 0.927 First order
F6 0.939 0.979 0.952 First order
F7 0.862 0.971 0.887 First order
Figure 1: (a) In vitro release profile of phenobarbital mouth dissolving film formulations F1, F2, and F4–F7 (b) In vitro release profile of phenobarbital 
mouth-dissolving film formulation F3 and LUMINAL
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that, formulations F3 is stable and retained their original 
properties with minor differences. The in vitro release profile 
of F3 at 30°C/60% RH and 40°C/75% RH conditions 
after 30 days was 95.114% and 92.316%, respectively, has 
indicated that no or minor alteration after storage.
In vivo animal safety study (irritation study)
The in vivo animal safety study is carried out to ensure safe 
use of films in oral cavity. Hamster cheek pouch was selected 
as model for study. Images of cheek pouch area were taken 
before and after placing of the films. The observation of 
images obtained of cheek pouch area of hamster before and 
after placing film shows no irritation or redness. Therefore, 
F3 formulation has shown good acceptability for oral use in 
treatment of epileptic attack or seizures. Obtained results 
have been shown in Figure 3 (a and b).
Figure 2: Scanning electron microscope image of (a) pure phenobarbital, (b) formulation F3 at t = 0 min, (c) formulation F3 at t = 1 min
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compliance, with all class of patients. From the in vivo 
animal safety studies, it was concluded that the optimized 
formulation had no irritation or redness on cheek pouch 
area of hamster and had good acceptability for oral use in 
treatment of epileptic attack or seizures.
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Figure 3a: Placebo film safety study on hamsters
Figure 3b: PBT F3 optimized film safety study on hamsters